Glenna Mileson - 04 Jan 2022 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role: Chief Financial Officer
Signature: /s/ Glenna Mileson
Issuer symbol: ATHA
Transactions as of: 04 Jan 2022
Net transactions value: +$20,159
Form type: 4
Filing time: 06 Jan 2022, 16:08:46 UTC
Previous filing: 10 Jun 2021
Next filing: 20 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATHA	Common Stock	Award	$11,647	+931	+1%	$12.51	90,755	18 Nov 2021	Direct	F1, F2, F3
transaction	ATHA	Common Stock	Options Exercise	$8,512	+6,305	+6.9%	$1.35	97,060	04 Jan 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATHA	Stock Option (Right to Buy)	Options Exercise	$0	-6,305	-100%	$0.000000^*	0	04 Jan 2022	Common Stock	6,305	$1.35	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2021 through November 18, 2021. This transaction is also exempt under Rule 16b-3(c).
F2	The Purchase Period ended November 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began May 18, 2021.
F3	In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2021.
F4	The shares subject to the option fully vested on January 1, 2022.